Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus.
A novel anti-hepatitis B virus (anti-HBV) agent, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil (L-FMAU), was synthesized and found to be a potent anti-HBV and anti-Epstein-Barr virus agent. Its in vitro potency was evaluated in 2.2.15 and H1 cells for anti-HBV and anti-Epstein-Barr virus activities, respectively. In vitro cytotoxicity in MT2, CEM, 2.2.15, and H1 cells was also assessed, and the results indicated high antiviral selectivities of L-FMAU in these cells.
Chu
C K
CK
Department of Medicinal Chemistry, College of Pharmacy, University of Georgia, Athens 30602, USA.
Ma
T
T
Shanmuganathan
K
K
Wang
C
C
Xiang
Y
Y
Pai
S B
SB
Yao
G Q
GQ
Sommadossi
J P
JP
Cheng
Y C
YC
D000998:Antiviral Agents / Q000494:pharmacology*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D004272:DNA, Mitochondrial / Q000032:analysis; D006515:Hepatitis B virus / Q000187:drug effects*; D004854:Herpesvirus 4, Human / Q000187:drug effects*; D006801:Humans; D014407:Tumor Cells, Cultured
D000998:Antiviral Agents; D004272:DNA, Mitochondrial; D001086:Arabinofuranosyluracil; C034935:clevudine